PTC Therapeutics (PTCT) Short Interest Ratio & Short Volume $46.73 -1.64 (-3.39%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$47.88 +1.15 (+2.45%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PTC Therapeutics Short Interest DataPTC Therapeutics (PTCT) has a short interest of 4.30 million shares, representing 5.90% of the float (the number of shares available for trading by the public). This marks a 13.46% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.9, indicating that it would take 5.9 days of the average trading volume of 792,174 shares to cover all short positions.Current Short Interest4,300,000 sharesPrevious Short Interest3,790,000 sharesChange Vs. Previous Month+13.46%Dollar Volume Sold Short$234.35 millionShort Interest Ratio5.9 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares78,869,000 sharesShort Percent of Float5.90%Today's Trading Volume987,958 sharesAverage Trading Volume792,174 sharesToday's Volume Vs. Average125% Short Selling PTC Therapeutics? Sign up to receive the latest short interest report for PTC Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartPTCT Short Interest Over TimePTCT Days to Cover Over TimePTCT Percentage of Float Shorted Over Time Remove Ads PTC Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/20254,300,000 shares $234.35 million +13.5%5.9%5.9 $54.50 2/28/20253,790,000 shares $209.44 million +2.4%5.2%5.3 $55.26 2/15/20253,700,000 shares $191.73 million -11.1%5.1%5.1 $51.82 1/31/20254,160,000 shares $190.86 million -1.9%N/A5.5 $45.88 1/15/20254,240,000 shares $179.22 million +1.0%N/A5.8 $42.27 12/31/20244,200,000 shares $189.59 million -8.5%N/A5.4 $45.14 12/15/20244,590,000 shares $212.84 million -0.2%N/A5.6 $46.37 11/30/20244,600,000 shares $201.85 million -1.5%N/A5.6 $43.88 11/15/20244,670,000 shares $183.20 million -4.5%N/A6.3 $39.23 10/31/20244,890,000 shares $195.21 million +4.9%N/A7.2 $39.92 Get the Latest News and Ratings for PTCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 10/15/20244,660,000 shares $175.03 million +9.1%N/A7 $37.56 9/30/20244,270,000 shares $158.42 million -18.2%N/A6.8 $37.10 9/15/20245,220,000 shares $177.43 million -7.3%N/A8.5 $33.99 8/31/20245,630,000 shares $198.85 million -5.4%N/A7.9 $35.32 8/15/20245,950,000 shares $196.59 million +3.7%N/A7.9 $33.04 7/31/20245,740,000 shares $194.30 million -3.7%N/A6.8 $33.85 7/15/20245,960,000 shares $197.45 million +6.4%N/A6.5 $33.13 6/30/20245,600,000 shares $171.25 million -23.8%N/A5.8 $30.58 6/15/20247,350,000 shares $263.20 million -1.9%N/A7.9 $35.81 5/31/20247,490,000 shares $272.34 million -16.0%N/A8.5 $36.36 5/15/20248,920,000 shares $300.25 million -10.2%N/A9.8 $33.66 4/30/20249,930,000 shares $319.25 million -2.7%N/A11.1 $32.15 4/15/202410,200,000 shares $261.94 million -0.6%N/A11.4 $25.68 3/31/202410,260,000 shares $298.46 million -5.8%N/A10.8 $29.09 3/15/202410,890,000 shares $321.80 million -4.5%N/A10.9 $29.55 2/29/202411,400,000 shares $321.37 million +9.8%N/A10.5 $28.19 2/15/202410,380,000 shares $266.66 million -6.0%N/A9.7 $25.69 1/31/202411,040,000 shares $288.03 million +10.7%N/A10.2 $26.09 1/15/20249,970,000 shares $272.48 million +1.9%N/A7.6 $27.33 12/31/20239,780,000 shares $269.54 million +6.1%N/A7.3 $27.56 12/15/20239,220,000 shares $261.76 million +3.7%N/A6.7 $28.39 11/30/20238,890,000 shares $204.65 million +10.0%N/A5.9 $23.02 11/15/20238,080,000 shares $167.82 million +9.5%N/A5.7 $20.77 10/31/20237,380,000 shares $138.38 million +5.1%N/A5.5 $18.75 10/15/20237,020,000 shares $143.14 million -12.4%N/A6 $20.39 9/30/20238,010,000 shares $179.50 million +8.5%N/A7.9 $22.41 9/15/20237,380,000 shares $193.80 million -0.3%N/A8.5 $26.26 8/31/20237,400,000 shares $292.30 million +2.6%N/A11.9 $39.50 8/15/20237,210,000 shares $297.48 million +2.3%N/A9.2 $41.26 7/31/20237,050,000 shares $284.40 million -5.5%N/A8.6 $40.34EU’s Action Takes Aim At US Retirees (Ad)Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free. Claim Your FREE 2025 Gold Guide Now—And Shield Your Wealth Before Gold Prices Skyrocket Further! 7/15/20237,460,000 shares $292.28 million -3.2%N/A8.6 $39.18 6/30/20237,710,000 shares $313.57 million +2.7%N/A8.9 $40.67 6/15/20237,510,000 shares $326.61 million +18.5%N/A8.5 $43.49 5/31/20236,340,000 shares $266.09 million +16.8%N/A7.3 $41.97 5/15/20235,430,000 shares $300.28 million +4.0%N/A7 $55.30 4/30/20235,220,000 shares $287.83 million -0.4%N/A7.1 $55.14 4/15/20235,240,000 shares $258.17 million -2.4%N/A7.5 $49.27 3/31/20235,370,000 shares $260.12 million -1.5%N/A7.3 $48.44 3/15/20235,450,000 shares $254.73 million +9.0%N/A7.5 $46.74 2/28/20235,000,000 shares $218.35 million +0.4%N/A7.4 $43.67 2/15/20234,980,000 shares $229.78 million -14.1%N/A7.8 $46.14 1/31/20235,800,000 shares $266.16 million +22.6%N/A9.1 $45.89 1/15/20234,730,000 shares $226.00 million -8.7%N/A6.9 $47.78 12/30/20225,180,000 shares $197.72 million +11.4%N/A7.9 $38.17 12/15/20224,650,000 shares $179.03 million +3.3%N/A7.7 $38.50 11/30/20224,500,000 shares $186.71 million -5.1%N/A7.1 $41.49 11/15/20224,740,000 shares $180.36 million -1.5%N/A7.3 $38.05 10/31/20224,810,000 shares $181.91 million +1.9%6.9%7.5 $37.82 10/15/20224,720,000 shares $243.74 million -6.2%6.8%7.6 $51.64 9/30/20225,030,000 shares $252.51 million -7.7%7.2%8.8 $50.20 9/15/20225,450,000 shares $292.39 million +8.1%7.8%8.7 $53.65 8/31/20225,040,000 shares $251.70 million -1.8%7.3%6.7 $49.94 8/15/20225,130,000 shares $271.48 million -1.0%7.4%6.6 $52.92 7/31/20225,180,000 shares $225.59 million -8.2%9.3%6.5 $43.55 7/15/20225,640,000 shares $247.14 million +11.9%10.2%7.3 $43.82 6/30/20225,040,000 shares $201.90 million -10.3%9.1%6.5 $40.06 6/15/20225,620,000 shares $147.19 million +3.3%10.1%7.3 $26.19 5/31/20225,440,000 shares $159.77 million +1.9%7.9%9 $29.37 5/15/20225,340,000 shares $168.96 million -11.7%7.7%9.2 $31.64 4/30/20226,050,000 shares $213.75 million +7.8%8.8%10.6 $35.33 4/15/20225,610,000 shares $249.65 million +4.5%8.1%9.9 $44.50 3/31/20225,370,000 shares $200.35 million -0.2%7.8%8 $37.31 3/15/20225,380,000 shares $184.10 million No Change7.8%7.7 $34.22 2/28/20225,380,000 shares $188.95 million +3.1%7.8%7.7 $35.12 2/15/20225,220,000 shares $215.12 million +5.7%7.6%6.9 $41.21 1/31/20224,940,000 shares $198.69 million -21.8%7.2%7 $40.22 1/15/20226,320,000 shares $276.50 million -7.9%9.2%9.3 $43.75 12/31/20216,860,000 shares $273.23 million -0.7%10.0%11.4 $39.83 12/15/20216,910,000 shares $262.65 million +16.7%10.1%13.6 $38.01 11/30/20215,920,000 shares $219.99 million -0.7%8.6%11.6 $37.16 11/15/20215,960,000 shares $231.49 million +10.8%8.7%12.7 $38.84 10/29/20215,380,000 shares $204.06 million +6.3%7.9%12 $37.93 10/15/20215,060,000 shares $192.74 million +7.7%7.4%11.3 $38.09 9/30/20214,700,000 shares $174.89 million +5.4%6.9%11.2 $37.21 9/15/20214,460,000 shares $180.90 million -0.9%6.5%10.7 $40.56 8/31/20214,500,000 shares $196.43 million -14.0%6.6%11.3 $43.65 8/13/20215,230,000 shares $209.25 million -1.9%7.7%12.9 $40.01 7/30/20215,330,000 shares $204.30 million +5.3%7.8%12.9 $38.33 7/15/20215,060,000 shares $217.48 million +4.8%7.4%10.2 $42.98 6/30/20214,830,000 shares $204.16 million +0.4%7.1%9.1 $42.27EU’s Action Takes Aim At US Retirees (Ad)Trump's Return Sparks Massive Gold Rush—Is Your 401(k) Ready for the Fallout? With President Trump back and global powers like China, Russia, and even Europe rapidly moving away from the U.S. dollar, central banks and financial giants are frantically buying gold at historic rates. This massive shift threatens your retirement savings with inflation and market instability—potentially worse than 2008. But you can protect yourself today by leveraging a little-known IRS loophole that lets you diversify your IRA or 401(k) into gold—tax-free and penalty-free. Claim Your FREE 2025 Gold Guide Now—And Shield Your Wealth Before Gold Prices Skyrocket Further! 6/15/20214,810,000 shares $210.73 million +1.1%7.1%8.8 $43.81 5/28/20214,760,000 shares $186.93 million -6.3%7.0%8.4 $39.27 5/14/20215,080,000 shares $195.02 million -2.7%N/A8.4 $38.39 4/30/20215,220,000 shares $221.85 million -0.8%N/A8.6 $42.50 4/15/20215,260,000 shares $251.95 million +0.8%N/A9.4 $47.90 3/31/20215,220,000 shares $244.30 million +2.2%N/A9.6 $46.80 3/15/20215,110,000 shares $298.68 million +7.1%N/A9.3 $58.45 2/26/20214,770,000 shares $263.26 million +19.0%N/A9 $55.19 2/12/20214,010,000 shares $253.73 million -2.0%N/A7.9 $63.28 1/29/20214,090,000 shares $230.55 million -2.6%N/A8.5 $56.37 1/15/20214,200,000 shares $288.62 million -11.0%N/A8.7 $68.72 12/31/20204,720,000 shares $288.30 million -3.9%N/A10.2 $61.08 12/15/20204,910,000 shares $324.11 million +5.4%N/A10.7 $66.01 11/30/20204,660,000 shares $298.19 million -0.6%N/A10 $63.99 11/15/20204,690,000 shares $281.87 million +4.0%N/A10.1 $60.10 10/30/20204,510,000 shares $243.04 million -9.6%N/A9.4 $53.89 10/15/20204,990,000 shares $261.23 million -3.5%N/A8.1 $52.35 9/30/20205,170,000 shares $241.70 million +4.2%N/A7.5 $46.75 9/15/20204,960,000 shares $236.05 million -13.0%N/A6.7 $47.59 8/31/20205,700,000 shares $281.69 million -9.4%N/A7.4 $49.42 8/14/20206,290,000 shares $308.34 million +22.4%N/A7.9 $49.02 7/31/20205,140,000 shares $238.14 million -6.0%N/A6.5 $46.33 7/15/20205,470,000 shares $297.90 million +4.2%N/A7.7 $54.46 6/30/20205,250,000 shares $265.86 million +7.4%N/A7.6 $50.64 6/15/20204,890,000 shares $240.73 million +11.1%N/A7 $49.23 5/29/20204,400,000 shares $223.12 million -1.4%N/A5.4 $50.71 5/15/20204,460,000 shares $217.78 million +10.7%N/A5.1 $48.83 4/30/20204,030,000 shares $205.21 million -7.4%N/A4.4 $50.92 4/15/20204,350,000 shares $206.10 million -3.3%N/A4.5 $47.38 PTCT Short Interest - Frequently Asked Questions What is PTC Therapeutics' current short interest? Short interest is the volume of PTC Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 4,300,000 shares of PTCT short. 5.90% of PTC Therapeutics' shares are currently sold short. Learn More on PTC Therapeutics' current short interest. What is a good short interest ratio for PTC Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. PTCT shares currently have a short interest ratio of 6.0. Learn More on PTC Therapeutics's short interest ratio. Which institutional investors are shorting PTC Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of PTC Therapeutics: Squarepoint Ops LLC, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Concourse Financial Group Securities Inc., JPMorgan Chase & Co., and Wolverine Asset Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for PTC Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.90% of PTC Therapeutics' floating shares are currently sold short. Is PTC Therapeutics' short interest increasing or decreasing? PTC Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 4,300,000 shares, an increase of 13.5% from the previous total of 3,790,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does PTC Therapeutics' short interest compare to its competitors? 5.90% of PTC Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to PTC Therapeutics: Summit Therapeutics Inc. (24.59%), Intra-Cellular Therapies, Inc. (2.58%), Moderna, Inc. (13.72%), Genmab A/S (0.48%), Dr. Reddy's Laboratories Limited (1.97%), Viatris Inc. (3.91%), Ascendis Pharma A/S (12.03%), Vaxcyte, Inc. (10.44%), Qiagen (1.72%), Roivant Sciences Ltd. (11.87%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short PTC Therapeutics stock? Short selling PTCT is an investing strategy that aims to generate trading profit from PTC Therapeutics as its price is falling. PTCT shares are trading down $1.64 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against PTC Therapeutics? A short squeeze for PTC Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of PTCT, which in turn drives the price of the stock up even further. How often is PTC Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including PTCT, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies SMMT Short Squeeze ITCI Short Squeeze MRNA Short Squeeze GMAB Short Squeeze RDY Short Squeeze VTRS Short Squeeze ASND Short Squeeze PCVX Short Squeeze QGEN Short Squeeze ROIV Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:PTCT) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
